Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zymeworks Inc (NQ: ZYME )

17.48 +0.08 (+0.46%)
Streaming Delayed Price Updated: 9:39 AM EST, Nov 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,948
Open 17.50
Bid (Size) 17.44 (6)
Ask (Size) 17.53 (6)
Prev. Close 17.40
Today's Range 17.41 - 17.55
52wk Range 7.130 - 17.70
Shares Outstanding 57,771,204
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors
Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancers 
From Zymeworks Inc.
Via GlobeNewswire

Performance

YTD
+68.40%
+68.40%
1 Month
+31.43%
+31.43%
3 Month
+70.87%
+70.87%
6 Month
+94.22%
+94.22%
1 Year
+140.44%
+140.44%

More News

Read More
Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
What Analysts Are Saying About Zymeworks Stock
Via Benzinga
Navigating 6 Analyst Ratings For Zymeworks
Via Benzinga
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
From Zymeworks Inc.
Via GlobeNewswire
Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare
Via Talk Markets
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
From Zymeworks Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.